持续依从使用含聚氨酯泡沫CPAP设备的癌症风险
本研究基于全国性倾向评分匹配的OSA患者队列,评估持续且依从使用含聚酯基聚氨酯泡沫的Philips Respironics CPAP设备是否与癌症风险增加相关。中位随访7.2年后,未发现癌症风险增加。既往研究因缺乏依从性数据无法评估依从患者的癌症风险。
要点
- 持续依从使用含PE-PUR泡沫的CPAP设备未增加癌症风险。
- 中位随访7.2年,基于倾向评分匹配的全国性队列。
- 既往研究报告的癌症风险增加在排除高吸烟率县后消失。
核心结论
- 持续且依从使用含聚酯基聚氨酯泡沫的Philips Respironics CPAP设备,在中位随访7.2年后未与癌症风险增加相关。
研究设计与样本
- 基于全国性OSA患者队列的倾向评分匹配研究。
主要发现
- 持续依从使用含PE-PUR泡沫的CPAP设备未增加癌症风险,中位随访7.2年。
- Kendzerska等报告1220例使用PR设备的OSA患者中位随访7.5年未增加所有癌症风险,但缺乏依从性数据。
- Palm等报告处方PUF-CPAP≥80%的县较<10%的县所有癌症和肺癌发病率增加,但排除高吸烟率县后关联消失。
临床怎么用
- 对于依从使用含PE-PUR泡沫CPAP设备的OSA患者,无需因癌症风险担忧而改变治疗决策。
局限性
- 既往研究缺乏治疗依从性数据,无法评估依从患者的癌症风险。
- Palm等的研究中癌症风险增加在排除高吸烟率县后消失,提示混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sustained and adherent CPAP therapy of obstructive sleep apnoea using Philips Respironics devices containing polyester-based polyurethane foam, was not associated with an increased risk of cancer after a median follow-up time of 7.2 years https://bit.ly/3vBpUQE On 14 June, 2021 Philipps Respironics (PR) emitted a voluntary recall notification for several sleep and respiratory care products, including continuous positive airway pressure (CPAP) devices used for obstructive sleep apnoea (OSA) therapy and ventilators. The polyester-based polyurethane (PE-PUR) sound abatement foam may break down into particles, which may enter the device's air tube and be inhaled or swallowed by the user. The volatile gas products (diethylene glycol, toluene di-isocyanate isomers, toluene diamine isomers) released during the degradation process have been suspected to present potential toxic and carcinogenic effects [1]. Whether prolonged exposure to these volatile compounds is associated with an increased risk of cancer in patients using PR devices for OSA is a crucial issue. Using clinical data from a retrospective longitudinal multicentre cohort linked with health administrative data, Kendzerska et al. [2] reported no increased all-cancer risk in 1220 patients treated for OSA with a PR device over a median follow-up time of 7.5 years. However, the lack of therapy adherence data did not make it possible to evaluate cancer risk in CPAP-adherent patients. Using propensity score matching within a nationwide study of patients with OSA, Palm et al. [3] reported an increased all-cancer and lung cancer incidence in counties prescribing ≥80% of CPAP devices containing polyurethane foam (PUF-CPAP) compared to patients from counties prescribing <10% of PUF-CPAP. However, the association disappeared in the sensitivity analysis excluding a Swedish county with known higher smoking rates.
引用
- Justeau G, Gervès-Pinquié C, Jouvenot M, et al. Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea. Eur Respir J. 2022. PMID: 35595314. doi:10.1183/13993003.00551-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。